公开(公告)号：US20150105444A1

公开(公告)日：2015-04-16

申请号：US14403914

申请日：2013-06-03

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Frank Rigo

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C07H21/00 ,  C12N2310/11 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/343 ,  C12N2320/33 ,  C12N2310/321 ,  C12N2310/3525

Abstract: The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.

Abstract translation: 本发明提供了包含与纤连蛋白转录物互补的寡核苷酸的化合物。 某些这样的化合物可用于与纤连蛋白转录物杂交，包括但不限于细胞中的纤连蛋白转录物。 在某些实施方案中，这种杂交导致纤连蛋白转录物剪接的调节。 在某些实施方案中，这些化合物用于治疗与纤维化相关的一种或多种症状。 在某些实施方案中，这些化合物用于治疗与肾纤维化相关的一种或多种症状。

公开(公告)号：US20150099792A1

公开(公告)日：2015-04-09

申请号：US14484638

申请日：2014-09-12

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Sanjay Bhanot

IPC: C12N15/113

CPC classification number: C12N15/1138 ,  A61K31/711 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/3525

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.

Abstract translation: 本文提供了用于减少动物中GCGR mRNA和蛋白质表达的方法，化合物和组合物。 这些方法，化合物和组合物可用于治疗，预防，延迟或改善代谢疾病，例如糖尿病或其症状。

公开(公告)号：US20150031747A1

公开(公告)日：2015-01-29

申请号：US14377614

申请日：2013-02-08

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Eric E. Swayze ,  Susan M. Freier

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/323 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor VII and treating, preventing, or slowing progression of thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof.

Abstract translation: 本文公开了用于减少因子VII并在有需要的个体中治疗，预防或减慢血栓栓塞并发症，过度增殖性疾病或炎性病症的进展的反义化合物和方法。

公开(公告)号：US20140371296A1

公开(公告)日：2014-12-18

申请号：US14368269

申请日：2012-12-21

Applicant: Isis Pharmaceuticals, Inc.

Inventor： C. Frank Bennett ,  Susan M. Freier ,  Eric G. Marcusson ,  Ssucheng J. Hsu ,  Robert A. MacLeod

IPC: C12N15/113

CPC classification number: C12N15/1136 ,  A61K31/711 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/321 ,  C12N2310/3525

Abstract: The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer.

Abstract translation: 本实施方案提供了用于在动物中减少转移相关的肺 - 腺癌 - 转录物-1（MALAT-1）RNA和/或蛋白质的表达的化合物和方法。 这些方法可用于治疗癌症，例如结肠癌，肠癌，肺癌（例如非小细胞肺癌），肝癌和/或前列腺癌。 在各个方面，癌症是原发性癌症。

公开(公告)号：US20140336237A1

公开(公告)日：2014-11-13

申请号：US14338880

申请日：2014-07-23

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Eric E. Swayze ,  Susan M. Freier ,  Robert A. MacLeod ,  Youngsoo Kim

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C07H21/00 ,  C07H21/04 ,  C12N15/00 ,  C12N15/11 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/3525

Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

Abstract translation: 本文公开了用于降低STAT3 mRNA和蛋白质表达的反义化合物和方法。 这些方法，化合物和组合物可用于治疗，预防或改善过度增殖性疾病。

公开(公告)号：US20140256797A1

公开(公告)日：2014-09-11

申请号：US14184984

申请日：2014-02-20

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Brett P. Monia ,  Susan M. Freier ,  Andrew M. Siwkowski ,  Shuling Guo

IPC: A61K31/712

CPC classification number: C12N15/113 ,  A61K31/712 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/52 ,  C12N2320/30 ,  C12N2310/3521

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.

Abstract translation: 本文提供了用于在动物中降低转甲状腺素蛋白mRNA和蛋白质表达的方法，化合物和组合物。 这些方法，化合物和组合物可用于治疗，预防，延迟或改善转甲状腺素蛋白淀粉样变性或其症状。

公开(公告)号：US20140235694A1

公开(公告)日：2014-08-21

申请号：US14152896

申请日：2014-01-10

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Sanjay Bhanot ,  Susan M. Freier

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/34 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12Y301/03048 ,  C12N2310/3525

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.

Abstract translation: 本文提供了用于降低动物体内PTP1B mRNA和蛋白质表达的方法，化合物和组合物。 这些方法，化合物和组合物可用于治疗，预防，延迟或改善代谢疾病，例如糖尿病或其症状。

公开(公告)号：US20140107180A1

公开(公告)日：2014-04-17

申请号：US14050574

申请日：2013-10-10

Applicant: ISIS PHARMACEUTICALS INC.

Inventor： Robert A. Macleod ,  Youngsoo Kim ,  Tianyuan Zhou ,  Susan M. Freier ,  Punit Seth ,  Eric Swayze ,  Brett Monia

IPC: C12N15/113 ,  A61K31/4166 ,  A61K31/7088

CPC classification number: C12N15/1138 ,  A61K31/4166 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3525

Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

Abstract translation: 某些实施方案涉及靶向人雄激素受体（AR）的化合物和组合物，用于抑制细胞中的雄激素受体水平，其可用于治疗癌症和抑制癌细胞生长或增殖的方法。

公开(公告)号：US20140080892A1

公开(公告)日：2014-03-20

申请号：US13915855

申请日：2013-06-12

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Sanjay Bhanot ,  Xing-Xian Yu ,  Susan M. Freier ,  Ravi Jain

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/7105

CPC classification number: C12N15/1138 ,  A61K31/7105 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.

Abstract translation: 提供反义化合物，组合物和方法用于调节成纤维细胞生长因子受体4（FGFR4）的表达。 组合物包含靶向编码成纤维细胞生长因子受体4的核酸的反义化合物，特别是反义寡核苷酸。使用这些化合物调节成纤维细胞生长因子受体4表达和治疗与成纤维细胞生长因子受体4表达相关的疾病的方法是 提供。